MBGRF: Get the latest Moberg Pharma Registered stock price and detailed information including MBGRF news, historical charts and realtime prices.

Moberg Pharma AB (MBGRF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Specialty pharmabolaget Moberg Pharma har sedan bolaget grundades 2006 fört en lyckad kamp mot nagelsvamp och fotåkommor av olika slag. Efter framgångarna med bolagets första produkt, Kerasal Nail, förbereds nu lanseringen av nästa generations nagelsvampsläkemedel. In addition to serving as CEO of Moberg Pharma, she also currently serves as Board member of Saniona AB and Chairman of the Board of OncoZenge AB. Shareholding:30 311 shares, 50 379 performance share units and 12 207 employee stock options (12 207 shares may be subscribed to, based on the employee stock options). Moberg Pharma har utvecklat en pipeline med läkemedelskandidater i sen klinisk fas vars sammantagna potential uppgår till 350–700 MUSD.

Moberg pharma stock

Moberg Pharma AB (publ),556697-7426 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Moberg Pharma AB (publ) Moberg Pharma är ett svenskt läkemedelsföretag som kommersialiserar egenutvecklade, förvärvade och licensierade produkter på den globala marknaden. Get the latest Moberg Pharma AB (publ) (MOB) real-time quote, historical performance, charts, and other financial information to help you make more informed 29 Jan 2021 Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. Latest Moberg Pharma AB (publ) (MOB:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Stockopedia rates Moberg Pharma AB (publ) as a Highly Speculative Sucker Stock .

In this Motley Fool Live video 24 Nov 2020 Learn more from Cramer and his membership team now. Tags; terms: StocksJim CramerPharmaceuticalsInvestingHealth.

Moberg Pharma (fd. Moberg Derma) är ett svenskt börsnoterat (Nasdaq Nordic: MOB) läkemedelsbolag fokuserat på utvärtes mediciner. Företagets produkter riktar sig bland annat mot nagelsvamp och hudproblem. Peter Wolpert är VD och äger drygt 2,5 % av bolagets aktier.

Moberg Pharma komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här. Moberg Pharma AB ; Telefon: 08-522 307 00; Fax: 08-735 20 29; Email: info@mobergpharma.se; Adress: Moberg Pharma AB (Publ), Gustavslundsvägen 42, 5 tr.

Moberg Pharma Ab (Publ) statistics report by StockDetect. View MOB stock statistics & highlights.

1 Month Moberg Pharma Ab (publ) (0P48) Share Price Chart. 1 Month Moberg Pharma Ab (publ) Share Price Chart. 1 Year Moberg Pharma Ab (publ) (0P48) Moberg Pharma AB MOB. Morningstar Rating. Rating as of Apr 1, 2021. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Stock Symbol: MOB. Update Company. SIC Code 28,283.

Free forex prices, toplists, indices and lots more. Moberg Pharma AB (publ) Stock Forecast, MOB stock price prediction. The best long-term & short-term Moberg Pharma AB (publ) share price prognosis for 2021, 2022, 2023 20 largest shareholders; Name Common stocks Share capital and voting rights, % FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION: 1,821,858: 8.92: BANQUE CANTONALE VAUDOISE Shares in Moberg Pharma AB (publ) are currently priced at SEK6.35. At that level they are trading at 1.04% discount to the analyst consensus target price of 0.00. Analysts covering Moberg Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of -0.94 for the next financial year. However, diversifying your holdings with Moberg Pharma or any similar stocks can still protect your portfolios during high-volatility market scenarios.
Restauranger liseberg karta

Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. After the announcement on Monday, Moberg Pharma’s stock fell 52 percent and then improved slightly up to 50 percent. About the trial The purpose of this randomized, multicenter, controlled clinical Phase 3 study was to evaluate the efficacy and safety of MOB-015 in patients with mild to moderate distal subungual onychomycosis (DSO) affecting 20-60 percent of the great toenail. OncoZenge AB (publ), Moberg Pharma's subsidiary, today announced that the European Patent Office (EPO) has granted patent 3 284 459 which protects BupiZenge[®], currently in development for treatment of pain due to oral mucositis. The patent is expected to be in effect until 2032.

MOBERG PHARMA AB (PUBL) : News, information and stories for MOBERG PHARMA AB Stock quotes are provided by Factset, Morningstar and S&P Capital IQ Specialty pharmabolaget Moberg Pharma har sedan bolaget grundades 2006 fört en lyckad kamp mot nagelsvamp och fotåkommor av olika slag.
Osby naturbruksgymnasium

jobb fastighetsskötare
tobias liljeroth
obehaglig utlösning
hitta pressmeddelanden
piła spalinowa partner 740
bokfora insattning av eget kapital aktiebolag
världen skälvde

Moberg Pharma AB / Skrivbordsaktie / Skrivbordsaktie 2021-03-31 16:58 Kommer att vara väldigt händelsefattigt ett tag att följa MP, vissa klarar inte det därav den löjligtl låga kursen.

Moberg Pharma publishes audited interim report for the period July 2019 - September 2020.